Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | GRM5 | P41594 | 1/20 | 0.90 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.58 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.58 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.58 |
| ▸ | GRIA3 | P42263 | 4/20 | 0.58 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.58 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.58 |
| ▸ | GRIK4 | Q16099 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL660028 | 1.00 | CYP1A2 (1.00) | CYP1A2RECQLGRM5GRIK1GRIA1 | |
| (R,S)-Ampa SCHEMBL6687427 | 0.74 | GRIA1 (1.00) | CYP1A2RECQLGRM5GRIK1GRIA1 | |
| (R,S)-Ampa SCHEMBL13957590 | 0.74 | GRIA1 (1.00) | CYP1A2RECQLGRM5GRIK1GRIA1 | |
| (S)-Ampa SCHEMBL29407234 | 0.74 | GRIA1 (1.00) | CYP1A2RECQLGRM5GRIK1GRIA1 | |
| (R,S)-Ampa SCHEMBL29469983 | 0.73 | BLM (1.00) | CYP1A2RECQLGRM5GRIK1GRIA1 | |
| SCHEMBL29486048 | 0.71 | GRIK1 (1.00) | CYP1A2RECQLGRM5GRIK1GRIA1 | |
| SCHEMBL27684359 | 0.69 | CYP1A2 (0.52) | CYP1A2RECQLGRM5MEN1CYP2C19 | |
| SCHEMBL13957587 | 0.68 | GRIA1 (1.00) | CYP1A2GRM5GRIK1GRIA1GRIA2 | |
| SCHEMBL31375382 | 0.68 | GRIA1 (1.00) | CYP1A2GRM5GRIK1GRIA1GRIA2 | |
| SCHEMBL28381546 | 0.67 | S1PR2 (0.60) | MAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263652-A1 | Treatment and/or Prevention of Inner Ear Conditions by Modulation of a Metabotropic Glutamate Receptor | HOUSE EAR INSTITUTE (US) | 2011-10-27 | — | — | US | claimed |
| EP-2344151-A2 | TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR | HOUSE EAR INSTITUTE (US) | 2011-07-20 | — | — | EP | claimed |
| WO-2010048095-A2 | TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR | HOUSE EAR INSTITUTE (US) | 2010-04-29 | — | — | WO | claimed |
| US-9173864-B2 | Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor | HOUSE EAR INSTITUTE (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150038464-A1 | METHODS OF INCREASING LIGHT RESPONSIVENESS IN A SUBJECT WITH RETINAL DEGENERATION | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2015-02-05 | — | — | US | disclosed |
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | AFRAXIS HOLDINGS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-8680099-B2 | 6-(ethynyl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2694504-A2 | 8-ETHYL-6-(ARYL)PYRIDO [2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | Afraxis Holdings, Inc. (US) | 2014-02-12 | — | — | EP | disclosed |
| WO-2011050206-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SINONASAL DISORDERS | OTONOMY, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011044535-A2 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011044264-A2 | PYRROLOPYRAZOLES FOR TREATING CNS DISORDERS | AFRAXIS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011009097-A2 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010071846-A2 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010048095-A2 | TREATMENT AND/OR PREVENTION OF INNER EAR CONDITIONS BY MODULATION OF A METABOTROPIC GLUTAMATE RECEPTOR | HOUSE EAR INSTITUTE (US) | 2010-04-29 | — | — | WO | disclosed |
| WO-2007029063-A2 | TREATMENT AND/OR PREVENTION OF PERVASIVE DEVELOPMENTAL DISORDERS | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2007-03-15 | — | — | WO | disclosed |
| US-20060264381-A1 | Methods of treating obsessive compulsive disorder | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-11-23 | — | — | US | disclosed |
| WO-2006121919-A2 | METHODS OF TREATING OBSESSIVE COMPULSIVE DISORDER | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264381-A1 | Methods of treating obsessive compulsive disorder | OXTR, MECP2, GRM5 | CYP1A2 4708/4885RECQL 3160/4885GRM5 3/4885 |
| US-20150038464-A1 | METHODS OF INCREASING LIGHT RESPONSIVENESS IN A SUBJECT WITH RETINAL DEGENERATION | GRM5, GRM1, GRIK5 | CYP1A2 4191/4885RECQL 3439/4885GRM5 1/4885 |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | CYP1A2 4685/4885RECQL 4303/4885GRM5 28/4885 |
| US-20140163026-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS AND CANCER | PAK2, PAK1, PAK6 | CYP1A2 4050/4885RECQL 1066/4885GRM5 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.